

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

1-7. (Cancelled)

8. (Currently Amended) A method of inhibiting ~~A method of treating a disorder characterized by angiogenesis or arteriogenesis in a patient in need thereof comprising administering active antithrombin III to said patient to a patient in need thereof.~~

9. (Currently Amended) The method as claimed in claim 8, wherein the active antithrombin III is the α isoform of antithrombin III, the β isoform of antithrombin III, a mixture of the two isoforms, or a concentrate of antithrombin III, ~~is administered.~~

10. (Currently Amended) The method as claimed in claim 8, wherein the ~~disorder is a~~ patient is suffering from retinopathy, neuropathy, or ~~[[an]]~~ infectious disease.

11. (Currently Amended) The method as claimed in claim 8, wherein the ~~disorder is a~~ patient is suffering from cancer.

12. (Currently Amended) The method as claimed in claim 11, wherein the cancer ~~[[is-a]]~~ is cancerous ulcer ~~[[or-a]]~~ or metastasis of cancerous ulcer.

13. (Currently Amended) The method as claimed in claim 8, wherein the ~~disorder is~~ patient is suffering from rheumatoid arthritis, psoriasis, endometriosis, chronic bronchitis, ~~[[or-a]]~~ or chronic inflammation of the gastrointestinal tract.

14. (Currently Amended) The method as claimed in claim 8, wherein the ~~antithrombin-III is prepared recombinantly or transgenically.~~

15. (Currently Amended) The method as claimed in claim 8, wherein the antithrombin III is administered intravenously, subcutaneously, intramuscularly or topically.

16. (Previously Presented) The method as claimed in claim 10, wherein the infectious disease is leprosy.

17. (New) The method of claim 8, wherein the active antithrombin III is free from latent antithrombin III.

18. (New) The method of claim 9, wherein the active antithrombin III is free from latent antithrombin III.

19. (New) The method of claim 9, wherein the active antithrombin III is a purified mixture of the α isoform of antithrombin III and the β isoform of antithrombin III, and is free from latent antithrombin III.